Cencora, Inc. (COR) Financials
PeriodQ3 FY2026
Published
Cencora reported revenue of $84.75 billion for Q3 FY2026, the quarter ended June 30, 2026, up 5.1% from a year earlier, and net income attributable to Cencora of $763.52 million, up 11.1%, or $3.94 per diluted share compared with $3.52. Gross profit was $3.61 billion, up 24.1%, helped by the consolidation of OneOncology, the oncology practice-management business Cencora took control of earlier in the fiscal year. Operating income was $1.12 billion, up 29.1%, and included a net credit from litigation and opioid-related items, among them a reduction of the opioid liability related to the dismissal of opioid litigation.
| Metric | Amount | vs. year ago |
|---|---|---|
| Revenue | $84,754,837,000 | up 5.1% |
| Net income | $763,518,000 | up 11.1% |
| Diluted EPS | $3.94 | up 11.9% |
| Gross profit | $3,607,235,000 | up 24.1% |
| Operating income | $1,120,217,000 | up 29.1% |
Company details
| Name | Cencora, Inc. |
|---|---|
| Ticker | COR |
| CIK | 0001140859 |
| Exchange | NYSE |
| State | Pennsylvania |
| Incorporation | Delaware |
| SIC | 5122 |
| Office | Trade & Services |
| Industry | Wholesale-Drugs, Proprietaries & Druggists' Sundries |
| Latest period covered | Q3 FY2026, ended 2026-06-30, 10-Q, accession 0001140859-26-000034 |
| Fiscal year end | 09/30 (MM/DD) |
| Next expected filing | 10-K around 2026-11-24 (predicted) |
Data files
- Financial statementsPage Annual financial statements plus the latest quarter: income statement, balance sheet, cash flow. Actual dollars, actual shares. Sourcing notes and uncertainties included, plus a figure_sources block linking each figure the filing tags to the line that prints it.
- 10-K and 10-Q summaryPage Qualitative synthesis of the latest 10-K + 10-Q: business, risk factors (quarter-over-quarter changes flagged), MD&A, legal proceedings, subsequent events.
- 8-K filings and eventsPage Digest of material 8-K filings: earnings headlines, management changes, capital-return and financing actions, governance. SEC accession numbers cited throughout.
FAQ · Cencora Q3 FY2026
How much revenue did Cencora report in Q3 FY2026?
Cencora reported revenue of $84.75 billion for Q3 FY2026, the quarter ended June 30, 2026. That is up 5.1% from $80.66 billion in the same quarter a year earlier.
What were Cencora's earnings per share in Q3 FY2026?
Cencora earned $3.94 per diluted share on a GAAP basis in Q3 FY2026, compared with $3.52 a year earlier. Net income attributable to Cencora was $763.52 million, up 11.1% from $687.40 million.
Why did Cencora's gross profit rise in Q3 FY2026?
Cencora's gross profit was $3.61 billion in Q3 FY2026, up 24.1% from $2.91 billion a year earlier, helped by the consolidation of OneOncology, the oncology practice-management business Cencora took control of earlier in the fiscal year.
What was Cencora's operating income in Q3 FY2026?
Cencora's operating income was $1.12 billion in Q3 FY2026, up 29.1% from $867.65 million a year earlier. The quarter included a net credit from litigation and opioid-related items, among them a reduction of the opioid liability related to the dismissal of opioid litigation.
Where can I get Cencora, Inc. (COR) financial data in machine-readable form?
Ticker Scout publishes Cencora, Inc.'s financial statements as JSON at https://tickerscout.ai/cor/financials.json, free, with no API key and no signup. The 10-K and 10-Q narrative and the 8-K events digest are published as Markdown at https://tickerscout.ai/cor/narrative.md and https://tickerscout.ai/cor/events.md. Cencora, Inc.'s SEC CIK is 0001140859. Every figure cites the SEC accession number it came from, so it can be checked against sec.gov.
When does Cencora, Inc. (COR) next file with the SEC?
Cencora, Inc. (COR) is expected to file its next Form 10-K with the SEC on or around November 24, 2026. That date is a projection rather than a company-announced date: it is derived from Cencora, Inc.'s own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 10-Q for Q3 FY2026, the period ended 2026-06-30, SEC accession 0001140859-26-000034.
Related companies
How this page was built
This page was built from Cencora, Inc.'s own filings with the SEC, read one at a time, and nothing on it is taken from a pre-tagged dataset, a data vendor or another website. The figures are on the company's own fiscal calendar and in actual dollars, as the filings report them. Where the filings do not support a figure, the record says so instead of reporting a zero; this period names three such gaps.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Data extracted from SEC filings (accession numbers cited in each file). The undated URLs hold the latest period and are replaced in place each quarter; every period also stays published at its own dated URL, which never changes. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.